The antihyperglycemic potential of pyraozolobenzothiazine 1,1-dioxide novel derivative in mice using integrated molecular pharmacological approach

Author:

Taj Saman1,Ashfaq Usman Ali1,Ahmad Matloob1,Noor Hasnat1,Ikram Ayesha1,Ahmed Rashid2,Tariq Muhammad2,Masoud Muhammad Shareef1,Hasan Anwarul3

Affiliation:

1. Government College University, Faisalabad

2. Mirpur University of Science and Technology

3. Qatar University

Abstract

AbstractDiabetes Mellitus (DM) is a extensively studied metabolic disease characterized by elevated blood sugar levels caused by inadequate insulin production, which subsequently leads to hyperglycemia. This study was intended to investigate thein silico,in vitro, andin vivoantidiabetic potential of pyrazolobenzothiazine derivatives. Molecular docking of pyrazolobenzothiazine derivatives was performed against α-glucosidase and α-amylase and compounds were selected based on docking score, bonding interactions and low root mean square deviation (RMSD).In vitroenzyme inhibition assay against α-glucosidase and α-amylase was performed usingp-nitrophenyl- α -D-glucopyranoside (PNPG) and starch substrate. Synthetic compound S1 exhibits little conformational changes during MD simulation run at 100ns. S1 also revealed effective IC50 values for α-glucosidase (3.91 µM) and α-amylase (8.89 µM) and an enzyme kinetic study showed low ki (-0.186, -1.267) and ki’ (-0.691, -1.78) values with the competitive type of inhibition for both enzymes α-glucosidase and α-amylase, respectively. Moreover, studies were conducted to check the effect of the synthetic compound in a mouse model. A low necrosis rate was observed in the liver, kidney, and pancreas through histology analysis performed on mice. Compound S1 also exhibited good biochemical profile with lower sugar level (110–115 mg/dL), increased insulin level (25–30 µM/L), and low level of cholesterol (85mg/dL) and creatinine (0.6 mg/dL) in blood. The treated mice group also exhibited a low % of glycated hemoglobin (3%). This study concludes that S1 is a new antidiabetic agent that helps lower blood glucose levels and minimizes the complications associated with type II diabetes.

Publisher

Research Square Platform LLC

Reference44 articles.

1. Takahashi, N., Deciding to Seek Help among Family Members Caring for Veterans with Diabetes Mellitus and Co-morbid Illnesses. 2016, UCLA.

2. Saeedi, P., et al., Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas. Diabetes research and clinical practice, 2019. 157: p. 107843.

3. Asiimwe, D., G.O. Mauti, and R. Kiconco, Prevalence and risk factors associated with type 2 diabetes in elderly patients aged 45–80 years at Kanungu District. Journal of diabetes research, 2020. 2020.

4. Diabetes Prevalence Survey of Pakistan (DPS-PAK): prevalence of type 2 diabetes mellitus and prediabetes using HbA1c: a population-based survey from Pakistan;Aamir AH;BMJ open,2019

5. Bashary, R., et al., An insight of alpha-amylase inhibitors as a valuable tool in the management of type 2 diabetes mellitus. Current diabetes reviews, 2020. 16(2): p. 117–136.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3